Phase 1a1b Study Evaluating Intravenous LY4337713 in Adults With FAP-Positive Solid Tumors to Assess Safety and Dosage

What this Trial Is About

This research is evaluating LY4337713 in adults with advanced or spread solid tumors that have high levels of a protein called fibroblast activation protein FAP. It focuses on assessing the safety, side effects, and effectiveness of LY4337713. The study also examines how the drug is absorbed, processed, and cleared from the body. The total duration for each participant is about five years. Participants will receive LY4337713 through intravenous IV infusions in escalating doses. The study includes several groups receiving different dose regimens during a dose escalation phase, followed by tumor-specific cohorts also treated with LY4337713 via IV. These treatments are given sequentially to evaluate dosage and safety. Throughout the study, participants will have regular assessments including imaging tests to monitor tumor response, blood tests to understand drug levels and effects, and safety evaluations. Researchers will measure outcomes such as dose-limiting toxicities in the first treatment cycle and tumor response over up to five years. The study monitors participants closely over a long period to gather detailed information on treatment effects and safety.

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors